Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug;11(8):2931-2935.
doi: 10.21037/tcr-22-141.

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report

Junfang Liu  1 , Lijun Shen  1 , Yunyao Qian  1 , Yunpeng Liu  1 , Minhong Su  1 , Li Yi  2
Affiliations
Case Reports

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report

Junfang Liu et al. Transl Cancer Res. 2022 Aug.

Abstract

Background: MET fusion is a rare type of structure rearrangement, reported only in 0.26% of non-small cell lung cancer (NSCLC). Some uncommon genomic variants, including MET fusions, have been detected with advanced detection technology. Therapeutic option for MET-rearranged NSCLC remains largely uncovered.

Case description: Herein, we described a 72-year-old male patient with a 10-year history of smoking who presented to our hospital with coughing, blood-tinged sputum, chest distress, and anhelation. He was diagnosed with stage IV lung adenocarcinoma harboring a CD47 (EX7)-MET (EX15) fusion, detected by next-generation sequencing (NGS). After one month of crizotinib treatment, the patient showed partial re-expansion of the collapsed right lower lobe, shrinkages of lymph node lesions, and reduced right pleural effusion. The patient achieved partial response (PR) to first-line treatment of crizotinib with a progression-free survival (PFS) of 8 months. Cabozantinib was subsequently administrated, and a short-term PR of fewer than three months was observed. The patient retained CD47-MET fusion and acquired MET D1228E at cabozantinib progression.

Conclusions: This case provided the first clinical evidence for the efficacy of crizotinib in CD47-MET rearranged NSCLC and suggested MET D1228E as a resistance mechanism. NGS is a powerful tool for identifying rare MET gene variants in patients with NSCLC, which should be encouraged in clinical practice.

Keywords: CD47-MET fusion; MET D1228E; Non-small cell lung cancer (NSCLC); cabozantinib; case report.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-141/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Tumor response to crizotinib treatment. (A) Baseline before treatment; (B) 1 month after crizotinib; (C) 5 months after crizotinib.
Figure 2
Figure 2
Illustration of CD47-MET fusion. The CD47-MET rearrangement had breakpoints in the CD47 intron 7 and MET intron 14, which conferred the fusion of CD47 exon 7 to MET exon 15. PMT, promoter; IVS, intervening sequence.
See this image and copyright information in PMC

References

    1. Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 2020;17:569-87. 10.1038/s41571-020-0377-z - DOI - PMC - PubMed
    1. Terlecka P, Krawczyk P, Grenda A, et al. MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer-A Review. J Pers Med 2021;11:1370. 10.3390/jpm11121370 - DOI - PMC - PubMed
    1. Cho JH, Ku BM, Sun JM, et al. KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. J Thorac Oncol 2018;13:e29-31. 10.1016/j.jtho.2017.10.014 - DOI - PubMed
    1. Zhu YC, Wang WX, Song ZB, et al. MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma. J Thorac Oncol 2018;13:e202-4. 10.1016/j.jtho.2018.05.009 - DOI - PubMed
    1. Zhu YC, Wang WX, Xu CW, et al. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing. Ann Oncol 2018;29:2392-3. 10.1093/annonc/mdy455 - DOI - PubMed

Publication types